ViiV Healthcare ’s new single-pill, two-drug HIV therapy, Dovato (dolutegravir/lamivudine), has met its primary endpoint in the Phase III TANGO study, indicating that levels of HIV continue to be suppressed after patients are switched from a TAF-containing three-drug regimen, the company announced on 10 July.
The TANGO study met the primary endpoint for non-inferiority of the two-drug versus three-drug regimen, based on the proportion of...







